Stent Trials Show Low TLR, MACE Rates

 
June 30, 2006

The TAXUS Express2 is a stainless steel stent that uses Paclitaxel and Translute polymer to control the drug release. Clinical trials consistently show low TLR and MACE rates compared to the bare metal control arm among a variety of patients and lesions. It is available in over-the-wire and monorail systems in a full product matrix, from 2.50 to 3.5 mm diameters and 8 to 32 mm lengths.

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.

Related News

Inpatients Who Have STEMI Heart Attacks More Likely to Die Than Outpatients

May 20, 2013 — If someone suffers a heart attack while walking down the street and is taken to the hospital quickly, his/her chances of survival are very good. But if someone has a heart attack...

Endovascular Repair Of Ruptured Aneurysms Saves More Lives Than Surgery

May 20, 2013 — Patients with ruptured...

CircuLite to Begin CE Mark Trial for Synergy IC VAD

May 20, 2013 — CircuLite Inc. announced that it has received approval from the Federal Agency for Medicines and Health Products in Belgium to commence the CE mark...

View all

Related Articles

Endovascular Repair Of Ruptured Aneurysms Saves More Lives Than Surgery

May 20, 2013 — Patients with ruptured...

University of Maryland Medical Center Launches Genetic-Testing Program For Cardiac Stent Patients

May 17, 2013 — Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their...

First Implant Made for Barostim neo Device to Treat Hypertension

May 17, 2013 — Prof. Dr. Béla Merkely and Dr. Péter Sótonyi at Semmelweis Egyetem Kardiológiai Központ in Hungary completed the first patient implant of the Barostim neo device...

View all